Gilead Sciences Inc.'s breakthrough therapy designation experience with its hepatitis C treatment Epclusa (sofosbuvir/velpatasvir) reflects the fluidity of the expedited program in a fast-moving therapeutic area.
The original breakthrough designation granted to Epclusa was subsequently narrowed by FDA due to the availability of other safe and...







